New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
07:03 EDTITMNInterMune announces resubmission of NDA for Perfernidone
InterMune announced that it has resubmitted its pirfenidone New Drug Application to the FDA in response to a Complete Response Letter received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis. Under the Prescription Drug User Fee Act, the FDA has 74 days after receipt of an NDA to evaluate the submission in order to determine if it is sufficiently complete. If in this 74-day period the FDA determines that the submission is complete, the review clock will be deemed to have started as of the date that the resubmission was initially received by the FDA. As the resubmission of an efficacy supplement, the submission of the ASCEND data represents a Class 2 resubmission that has a target FDA review of six months under PDUFA V.
News For ITMN From The Last 14 Days
Check below for free stories on ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
11:19 EDTITMNInterMune July weekly volatility elevated
Subscribe for More Information
July 17, 2014
12:42 EDTITMNInterMune receives FDA Breakthrough Therapy Designation for pirfenidone
InterMune announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. FDA. This designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Pirfenidone is an investigational treatment for adult patients with idiopathic pulmonary fibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use